BioStock: First patient enrolled in Cereno Scientific's phase II study

Cereno Scientific has announced enrolling the first patient in its phase II clinical study with lead drug candidate CS1 in pulmonary arterial hypertension. This is a key milestone for the company as it advances its ambition to develop new and better treatments for cardiovascular diseases.

Read the article at biostock.se:

https://www.biostock.se/en/2022/07/first-patient-enrolled-in-cereno-scientifics-phase-ii-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/